FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death (any cause) · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Intensive insulin therapy may leads to lower occurrence of CIP/CIM ‐ in total population randomised compared with conventional insulin therapy (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Intensive insulin therapy probably leads to lower occurrence of CIP/CIM ‐ in screened population compared with conventional insulin therapy (moderate certainty).
1 finding from 1 review
Duration of mechanical ventilation · critically ill patients
1 finding from 1 review
Duration of ICU stay · critically ill patients
1 finding from 1 review
Death ‐ at 30 days after ICU admission, in total population randomised · critically ill patients
Intensive insulin therapy showed no clear difference in death ‐ at 30 days after ICU admission, in total population randomised compared with conventional insulin therapy (high certainty).
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Intensive insulin therapy showed no clear difference in death ‐ at 180 days after ICU admission, in total population… compared with conventional insulin therapy (moderate certainty).
1 finding from 1 review
Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
1 finding from 1 review
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether insulin plus glucagon changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether insulin plus glucagon changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%) · adults with CFRD
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults with CFRD
Summary of findings: insulin showed no clear difference in FEV1 % predicted: change from baseline compared with placebo (low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · adults with CFRD
Summary of findings: insulin showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).
1 finding from 1 review